UOC
UTHR icon

UBS O'Connor’s United Therapeutics UTHR Stock Holding History

UBS O'Connor’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,254
Closed -$718K – 609
2024
Q2 		$718K Buy
2,254
+726
+48% +$192K 0.02% 339
2024
Q1 		$351K Sell
1,528
-3,515
-70% -$793K 0.01% 359
2023
Q4 		$1.11M Sell
5,043
-7,482
-60% -$1.72M 0.03% 253
2023
Q3 		$2.83M Sell
12,525
-2,000
-14% -$461K 0.05% 183
2023
Q2 		$3.21M Buy
14,525
+1,952
+16% +$432K 0.07% 182
2023
Q1 		$2.82M Buy
12,573
+1,051
+9% +$259K 0.07% 214
2022
Q4 		$3.2M Sell
11,522
-1,640
-12% -$414K 0.06% 301
2022
Q3 		$2.76M Buy
13,162
+4,900
+59% +$1.1M 0.03% 465
2022
Q2 		$1.95M Buy
8,262
+1,336
+19% +$272K 0.02% 661
2022
Q1 		$1.24M Buy
+6,926
New +$1.32M 0.01% 662

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

UBS O'Connor's UTHR Position: Q3 2024 in Review

UBS O'Connor sold out of United Therapeutics (UTHR) in Q3 2024, closing a stake of 2,254 shares — an estimated $718K sold.

UBS O'Connor first reported a position in UTHR in Q1 2022 and held it in 10 quarters. The position peaked at $3.21M in Q2 2023. 625 funds tracked by Wall St. Rank hold UTHR as of Q3 2024.

  • UBS O'Connor reported no remaining United Therapeutics position as of Q3 2024 after selling out during the quarter.
  • UBS O'Connor sold 2,254 United Therapeutics shares in Q3 2024, an estimated $718K.
  • UBS O'Connor first reported a position in United Therapeutics in Q1 2022 and held it in 10 quarters.
  • UBS O'Connor's United Therapeutics position peaked at $3.21M in Q2 2023.
  • 625 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2024.

Based on UBS O'Connor's 13F filing for Q3 2024, filed 14 Nov 2024.